ALS and causative genes
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease affecting healthy middleaged individuals. The disease course is rapidly progressive, and the eventual respiratory muscle weakness results in death within a few years of onset. More than 90% of ALS cases are sporadic in which the cause of ALS is largely unknown. The remaining cases of ALS are familial (approximately 5-10% of all ALS cases), in approximately half of these cases mutations in several genes have been demonstrated. At present, more than 20 different mutant genes are known to cause familial ALS (Ferraiuolo et al., 2011; Rademakers and van Blitterswijk, 2013) , including SOD1 (Rosen et al., 1993) , chromosome 9 open reading frame 72 (C9ORF72) (DeJesusHernandez et al., 2011; Renton et al., 2011) , TAR DNA-binding protein (TARDBP) (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008) , Fused in sarcoma (FUS) (Kwiatkowski et al., 2009; Vance et al., 2009 ). These genes account for about 50% of all familial ALS cases (Ferraiuolo et al., 2011) , while only a small percentage of sporadic ALS cases had mutations found in these genes. Therefore, it is likely that multiple different molecular mechanisms underlie sporadic ALS and each familial ALS that are associated with different individual causative genes; TDP-43 is a pathological hallmark of the majority of ALS patients, and both TDP-43 pathology and inefficient editing of the GluA2 Q/R site occur concomitantly in many of the motor neurons of patients with sporadic ALS (Aizawa et al., 2010) . In TARDBP-associated ALS, although TDP-43 pathology is the pathological characteristics as in sporadic ALS that carry wild-type TARDBP gene, ADAR2 downregulation has not been demonstrated. Likewise, neither of these two abnormalities were observed in the motor neurons of SOD1-associated ALS patients or SOD1 transgenic animals (Kawahara et al., 2006; Mackenzie et al., 2007; Robertson et al., 2007; Tan et al., 2007) . Therefore, elucidation of pathogenic mechanisms specific for sporadic ALS and individual familial ALS cases will be necessary to develop new gene-targeting therapeutic strategies.
2.
Abnormal RNA editing and ADAR2 in sporadic ALS motor neurons GluA2 (previously called GluR2 or GluR-B) is a subunit of the L-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and pre-mRNA of GluA2 is normally subjected to RNA editing at the glutamine/arginine (Q/R) site. The adenosine at the Q/R site of GluA2 pre-mRNA is converted to inosine (A-to-I conversion) and the genomic CAG codon for Q is converted to a CIG codon in mRNA, and CIG is read as CGG, which is a codon for R during translation. Additionally, because the A-to-I conversion invariably occurs at the Q/R site, all of the GluA2 mRNA expressed in neurons is edited to an R at this site (GluA2R) (Kawahara et al., 2004; Sommer et al., 1991; Takuma et al., 1999) .
In the spinal motor neurons of the majority of sporadic ALS patients, RNA editing of GluA2 is inefficient at the glultamine/ arginine (Q/R) site, and abnormal Q/R site-unedited GluA2 (GluA2Q) is expressed in approximately half of remaining motor neurons in an individual patient (Hideyama et al., 2012b; Kawahara et al., 2004; Takuma et al., 1999) . The expression of GluA2Q in motor neurons has been demonstrated in the majority of sporadic ALS patients so far examined (430 cases) irrespective of the difference in clinical manifestations (Hideyama et al., 2012b) , whereas motor neurons from control subjects and patients with other diseases, including other motor neurons diseases, including spinal and bulbar muscular atrophy and SOD1-associated ALS do not express GluA2Q (Kawahara et al., 2006) .
Functional AMPA receptors are homo-or hetero-tetramers of four subunits called GluA1-GluA4. The nucleotide sequence in the genomic Q/R site is CAG (a codon for Q) in all of AMPA receptor subunits, and only GluA2 expresses R at the Q/R site resulting from A-to-I conversion (Seeburg, 2002) . AMPA receptors are either Ca 2þ -permeable or -impermeable, which is determined by whether the AMPA receptor has GluA2R in its subunit or not; only the AMPA receptors having GluA2R is Ca 2þ -impermeable, whereas those composed of only Q/R site-unedited subunits, including GluA2Q are Ca 2þ -permeable (Seeburg, 2002) . A-to-I conversion at the GluA2 Q/R site occurs in all GluA2 expressed in neurons and virtually all neurons in the mammalian brain express only GluA2R (Seeburg, 2002) . Additionally, failure of Q-to-R conversion at this site produces Ca 2þ -permeable AMPA receptors that results in increased excitation of neurons, which has been shown to culminate in fatal status epilepticus in mice (Brusa et al., 1995; Feldmeyer et al., 1999; Higuchi et al., 2000) .
Adenosine deaminase acting on RNA 2 (ADAR2) specifically catalyzes the A-to-I conversion at the Q/R site of GluA2 premRNA (Higuchi et al., 1993 (Higuchi et al., , 2000 . In mammals, there are three structurally related members (ADAR1, ADAR2 and ADAR3) in the ADAR family. ADARs possess two or three double strand RNA binding domains in the N-terminal region and one deaminase domain in the C-terminal region (Hogg et al., 2011) . Although ADAR1 and ADAR2 actively catalyze A-to-I conversion with different substrate spectra, ADAR3 that is specifically expressed in the brain, predominantly in the white matter, exhibits no editing activity in either naturally occurring or artificial substrates (Chen et al., 2000; Melcher et al., 1996) .
In accordance with these studies on mammalian brains, a recent study demonstrated that the expression levels of ADAR2, but not of ADAR1 or ADAR3, were significantly decreased in the motor neurons of sporadic ALS patients compared to normal and disease control cases (Hideyama et al., 2012b) . Previous studies on gene expression in a global scale has not demonstrated the reduction of ADAR2 gene expression in ALS motor neurons (Jiang et al., 2005) , presumably due to the technical reasons. The reduction of ADAR2 expression was extensive in ALS motor neurons expressing GluA2Q, and mild but significant in those expressing only GluA2R (Hideyama et al., 2012b) . These results indicate that ADAR2 downregulation is a selective, profound and diseasespecific pathological change in motor neurons from sporadic ALS patients.
Recently, by using global genome wide and RNA sequencing analysis, it is now recognized that ADAR2 is involved in the editing of a large number of RNAs including GluA2 (Cattenoz et al., 2013; Li et al., 2009; Maas et al., 2011; Peng et al., 2012; Zhu et al., 2013) . The reduction of ADAR2 in motor neurons from ALS patients may induce various defects, including the potential alteration in the role for RNA splicing (Solomon et al., 2013) and control of neuronal excitability (Li et al., 2013) . Furthermore, hnRNP A2/B1, known as an enhancer of RNA editing (Garncarz et al., 2013) , was recently reported to link to ALS and frontotemporal dementia (FTD) (Kim et al., 2013) . Although the functional significance is not clear, there is a report regarding association of ALS and abnormal editing of the glutamate transporter EAAT2, of which downregulation was previously discussed for the pathogenic role in ALS (Flomen and Makoff, 2011) . These reports may also suggest the role of altered RNA editing in the pathogenesis of ALS.
3.
Abnormal RNA editing and motor neuron death Pathogenic roles of inefficient RNA editing at the GluA2 Q/R site for sporadic ALS have been demonstrated in the motor neuron-selective conditional ADAR2 knockout (AR2) mice carrying floxed ADAR2 alleles that are targeted by Cre expressed under the control of vesicular acetylcholine transporter (VAChT) promotor (Hideyama et al., 2010) . These AR2 mice displayed a slow and progressive motor dysfunction attributable to loss of ADAR2-lacking motor neurons and their neuromuscular motor units. Because the expression of GluA2R by genetic engineering of the endogenous GluA2 gene rescued ADAR2-lacking motor neurons from death in AR2 mice, these results indicate that the death of motor neurons was caused by a Ca 2þ -permeable AMPA receptor-mediated mechanism resulting from inefficient RNA editing at the GluA2 Q/R site (Hideyama et al., 2010) . In heterozygous AR2 (AR2H) mice in which one ADAR2 gene allele was ablated in motor neurons, the motor neurons with reduced ADAR2 expressed GluA2Q mRNA, although to a lesser extent compared to ADAR2-lacking motor neurons in homozygous AR2 mice, and underwent a slow death when examined at 12 months of age (Hideyama and Kwak, 2011) . Taken together, expression of GluA2Q, even if it is a small proportion of all AMPA receptors, is not favorable for the survival of motor neurons in mice and expression of ADAR2 at a level sufficient to edit all of the GluA2 mRNA rather than the expression level of ADAR2 per se is the critical factor for motor neuron survival. The critical role of GluA2 Q/R siteediting in neuronal death in mice indicates the pathogenic role of GluA2Q expression in ALS motor neurons (Hideyama et al., 2010) . Therefore, insufficient levels of ADAR2 that leads to the expression of GluA2Q are a likely cause of death of motor neurons in sporadic ALS.
TDP-43 and RNA editing
The abnormal processing and mislocalization of TAR DNAbinding protein-43 (TDP-43) in motor neurons is known as a pathological hallmark of sporadic ALS (Arai et al., 2006; Neumann et al., 2006) (Fig. 1) . TDP-43 is a nuclear protein involved in the regulation of RNA processing (Buratti and Wild Type AR2 Sporadic ALS Baralle, 2010; Colombrita et al., 2012; Daoud et al., 2009; Gendron and Petrucelli, 2011; Iguchi et al., 2009; Johnson et al., 2009; Nonaka et al., 2009; Polymenidou et al., 2011; Sephton et al., 2011; Tollervey et al., 2011; Zhang et al., 2009 ). TDP-43 pathology was also observed in pathological brain regions of Frontotemporal Lobar Degeneration (FTLD) and Alzheimer's disease (Wilson et al., 2011) in which RNA editing was efficient, suggesting that there were several different causes for TDP-43 pathology. TDP-43 pathology consists of a combination of molecular abnormalities including absence from the nucleus, where it normally resides, mislocalization to abnormal cytoplasmic inclusions and abnormal fragmentation and hyperphosphorylation (Arai et al., 2006; ChenPlotkin et al., 2010; Hasegawa et al., 2008; Neumann et al., 2006) . TDP-43 pathology is believed to be initiated from the formation of small aggregates that are generated by fragmentation of TDP-43 in the cytoplasm, which serve as seeds for large inclusions that increase in size with sequestration of full-length and fragments of TDP-43 (Chen-Plotkin et al., 2010) . Although protease-dependent cleavage of TDP-43 is likely a trigger for TDP-43 pathology, neither the proteases involved nor the mechanism of protease activation are known. TDP-43 pathology is rarely, if ever, observed in the motor neurons of patients who have SOD1-associated ALS or in SOD1 Tg animals (Mackenzie et al., 2007; Robertson et al., 2007; Tan et al., 2007) . Moreover, inefficient RNA editing at the GluA2 Q/R site in motor neurons of sporadic ALS does not occur in SOD1 Tg rats (Aizawa et al., 2010; Kawahara et al., 2006) . The difference, in light of TDP-43 processing and ADAR2 regulation, between these two ALS model lines suggests a mechanistic difference between SOD1-associated ALS and sporadic ALS. Notably, disease-specific abnormalities of both ADAR2 underactivity and TDP-43 pathology were concomitantly observed in the same motor neurons of sporadic ALS patients, suggesting a molecular link between these two molecular abnormalities (Aizawa et al., 2010) . Furthermore, these two molecular abnormalities in motor neurons were observed not only in sporadic ALS patients but also in elderly humans and mice (Geser et al., 2010; Hideyama et al., 2012a) , providing evidence that there is an intimate molecular linkage between both (Fig. 2) .
Experiments using various lines of cultured cells demonstrated that none of TDP-43 overexpression, TDP-43 knockdown, TDP-43 C-terminal fragments or TDP-43 mutations, changed the expression levels of ADAR2 (Yamashita et al., 2012b) . These results suggest that the abnormal processing of TDP-43 is not an upstream event of inefficient GluA2 Q/R site RNA editing in the motor neurons of sporadic ALS patients.
The downregulation of ADAR2 in motor neurons of sporadic ALS patients occurred before RNA editing at the GluA2 Q/R site was inefficient, and TDP-43 pathology was generated only in motor neurons that have very low ADAR2 expression (Hideyama et al., 2012b) . ADAR2-lacking motor neurons in AR2 and AR2H mice underwent death via a Ca 2þ -permeable AMPA receptormediated mechanism (Hideyama et al., 2010; Hideyama and Kwak, 2011) , and exhibited loss of TDP-43 from the nucleus and TDP-43-containing abnormal aggregates in the cytoplasm (Figs. 1 and 3) (Yamashita et al., 2012a) . In vitro calpain assay demonstrated that TDP-43 was specifically cleaved by calpains. Cleavage of TDP-43 was inhibited by endogenous and exogenous calpain inhibitors both in vivo and in vitro and when the AR2 mice were engineered to express Ca TDP-43 Merge Fig. 3 -TDP-43 pathology and ADAR2 in spinal motor neurons (AHCs) (AR2 and AR2H). Immunofluorescence assays revealed that ADAR2 (red) and TDP-43 (green) both localize to the nucleus in control AHCs.TDP-43 immunoreactivity was absent in AHCs that lack ADAR2 in AR2 mice (arrow). AHCs with low immunoreactivity for ADAR2 showed TDP-43 immunoreactivity in the cytoplasm and TDP-43-positive cytoplasmic aggregates in heterozygous AR2 mice (AR2H) (arrow). TOPRO-3 is a cellular maker (blue).
b r a i n r e s e a r c h 1 5 8 4 ( 2 0 1 4 ) 2 8 -3 8 mice (Hideyama et al., 2010; Kask et al., 1998) . Conversely, both TDP-43 cleavage and mislocalization in the neurons were exaggerated in calpastatin knockout mice. These results indicated that the fragmentation and abnormal localization of TDP-43 observed in AR2 and AR2H mice were dependent on the activation of calpain through Ca 2þ -permeable AMPA receptors (Yamashita et al., 2012a) .
The Ca 2þ -dependent serine protease calpain cleaved TDP-43 at several positions in the C-terminal region and the resulting N-terminal fragments were prone to aggregation (Fig. 4) (Yamashita et al., 2012a ). In the brains and spinal cords of ALS patients, calpain is more active compared to normal control subjects and calpain-dependent TDP-43 fragments were demonstrated in the lysates and sarkosyl-insoluble fraction, suggesting that the calpain-dependent cleavage of TDP-43 may be involved in the pathogenesis of TDP-43 pathology of ALS motor neurons the same as observed in AR2 mouse motor neurons (Yamashita et al., 2012a) .
There were many reports indicating that the TDP-43 cleavage was caused by caspase-3 (Dormann et al., 2009; Igaz et al., 2009; Zhang et al., 2007) and loss of function of the progranulin has been suggested to lead to caspase-3 activation. The caspase-3-dependent proteolysis of the TDP-43 generated C-terminal fragments (CTFs) but researchers demonstrated the presence of TDP-43 CTFs that were generated by caspasedependent and -independent cleavage (Herskowitz et al., 2012; Nishimoto et al., 2009; Nonaka et al., 2009 ) and fragments consistent with those generated by cleavage with both calpain and caspase-3 was demonstrated in sporadic FTLD-ALS brain and spinal cord extracts (Yamashita et al., 2012a) . These observations suggest that caspase-3-dependent cleavage of TDP-43 may participate in TDP-43 pathology by cleaving the full-length and calpain-dependent fragments of TDP-43 into aggregation-prone fragments. However, caspase-3 cleaved TDP-43 far less effectively than calpain (Yamashita et al., 2012a ) and caspase-3 was activated after the activation of calpain in the brains of excitotoxic model animals (Takano et al., 2005) , suggesting the minor participation of caspases in TDP-43 compared to calpains.
Taken together, these results indicate that the calpaindependent cleavage of TDP-43 plays a crucial role in ALS pathology (Fig. 5) , although the link between the formation of TDP-43 aggregation and cell death is unknown.
5.
TARDBP-associated ALS and Calpain TDP-43 pathology appears in the motor neurons of patients with ALS associated with mutations in the TARDBP gene as well as sporadic ALS patients who express wild-type TDP-43 (Arai et al., 2006; Chen-Plotkin et al., 2010; Hasegawa et al., 2008; Lagier-Tourenne et al., 2010; Neumann et al., 2006) . Although an increased vulnerability of cultured cells expressing mutant TDP-43 compared to those expressing wild- 
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Other class of Neurons Motor Neuron Fig. 6 -Schematic illustration of the molecular mechanism underlying TARDBP-ALS motor neuron and other class of neurons. The expression of ADAR2 is normal, and Q/R site-edited GluA2 is expressed with normal activation of calpain in TARDBP-ALS.
In TARDBP-ALS motor neurons, calpain activity is higher than in other classes of neurons presumably due to the higher expression level of GluA2-lacking Ca 2þ -permeable AMPAR. The increased vulnerability of mutant TDP-43 to calpain-mediated cleavage in motor neurons with physiologically high calpain activity generates more abundant highly aggregation-prone fragments in the motor neurons than in other classes of neurons of TARDBP-ALS patients.
type TDP-43 has been demonstrated (Gitcho et al., 2008; Sreedharan et al., 2008) , molecular mechanisms whereby mutant and wild-type TDP-43 exhibit similar pathology have not been elucidated. Recent finding that ALS-linked mutant TDP-43 (A315T, M337V) was more effectively cleaved by calpains than wild-type TDP-43 suggested that increased liability to calpain-dependent cleavage was involved in the TDP-43 pathology observed in the motor neurons of TARDBP-ALS patients. In addition, the increased susceptibility of mutant TDP-43 to calpain cleavage enables to explain the finding that patients who have mutations in the TARDBP gene exhibit an ALS phenotype but not, or at least very infrequently, a frontotemporal dementia (FTD) phenotype (ChenPlotkin et al., 2010) . Ca 2þ influx through the AMPA receptors is known to be greater in the spinal motor neurons than in the dorsal horn neurons in a primary culture of spinal cord neurons (Carriedo et al., 1996) , and calpain activity in the spinal motor neurons was greater than in other neurons, such as cortical and dorsal horn neuron of autopsied human subjects free from neurological diseases (Yamashita et al., 2012a) . Spinal motor neurons express relatively low levels of GluA2 compared to other classes of neurons in humans and rodents (Carriedo et al., 1996; Kawahara et al., 2003; Sun et al., 2005) , indicating that more abundant AMPA receptors lacking GluA2 resulted in higher Ca 2þ influx through AMPA receptors and calpain activity in motor neurons than in other class of neurons (Fig. 6 ). These lines of evidence suggest that a greater amount of TDP-43 fragments would be generated in the motor neurons in which Ca 2þ -permeable AMPA receptors lacking GluA2 are abundantly expressed, and the motor neuron-prone generation of TDP-43 pathology results in ALS phenotype in TARDBP patients (Chen-Plotkin et al., 2010; Lagier-Tourenne et al., 2010) . Therefore, although the role of calpain is critical in TDP-43 pathology, different mechanisms may enhance calpain-dependent TDP-43 cleavage between sporadic ALS and TARDBP-ALS. In sporadic ALS, activation of calpain by increased Ca 2þ influx through the upregulation of Ca 2þ -permeable AMPA receptors containing GluA2Q enhanced TDP-43 cleavage, whereas the increased vulnerability of mutant TDP-43 to calpain-mediated cleavage generates abnormal TDP-43 fragments in TARDBP-ALS motor neurons where calpain activity is higher than in other classes of neurons presumably due to the higher expression level of GluA2-lacking Ca 2þ -permeable AMPA receptors.
In motor neurons of both sporadic ALS and TARDBP-associated ALS, highly aggregation-prone calpain-dependent TDP-43 fragments generated cytoplasmic inclusions to which nucleocytoplasm shuttling TDP-43 was sequestered and disappeared from the nucleus (Figs. 5 and 6) (Yamashita et al., 2012a) . These results suggest that the same pathology would be generated from different mechanisms and that we should be prudent to assess the pathological hallmark as a disease hallmark.
6.
TDP-43 pathology in other neurological diseases TDP-43 pathology is observed not only in ALS motor neurons and FTLD-TDP cortical neurons but also in pathological brain regions of various other neurological diseases, including Alzheimer's disease (Wilson et al., 2011) and traumatic brain injury (McKee et al., 2010) , as well as in the CNS of animals exposed to various adverse conditions, including sciatic axotomies (Moisse et al., 2009 ) and brain ischemia (Kanazawa et al., 2011) . Because Ca 2þ dysregulation and calpain activation have been reported in various diseases (Lopatniuk and Witkowski, 2011) , calpain activated via various abnormal Ca 2þ signaling pathways could play important roles for TDP-43 pathology. In fact, age-associated calpain activation may be involved in the mechanism underlying mislocalization of TDP-43 from the nucleus to the cytoplasm that is observed in the cortical neurons of normal elderly people (Geser et al., 2010) and motor neurons of aged mice (Hideyama et al., 2012a) . Scrutiny of the roles of various pathways causing Ca 2þ dysregulation in the pathological conditions in TDP-43 may improve our knowledge about the mechanism generating TDP-43 pathology in various neurological diseases other than ALS.
Conclusion and future directions
In this review, we summarized the evidence indicating the role of inefficient RNA editing in the pathogenesis of sporadic ALS. These molecular abnormalities cause death of motor neurons and TDP-43 pathology in the motor neurons of the conditional ADAR2 knockout mouse, a mechanistic model of sporadic ALS. However, we still do not know how the mislocalization of TDP-43 leads motor neurons to death or whether the mislocalization of TDP-43 occurs in the death cascade or merely an associated phenomenon observed downstream of ADAR2 downregulation. Another unresolved question is why ADAR2 is downregulated in ALS motor neurons. Recent studies on dysfunction of some ALS associated genes seem to provide us a clue for the mechanism. ALS-linked genes encode proteins involved in RNA processing, and using iPS cells, fibroblasts and brains from patients carrying expansion of GGGGCC repeat in C9orf72 gene, an ALS-linked gene, several reports showed formation of abnormal RNA foci in which some RNAbinding proteins, including ADARB2 (or ADAR3) protein, a member of the RNA editing enzyme family, were demonstrated (Donnelly et al., 2013; Gendron et al., 2013; LagierTourenne et al., 2013; Sareen et al., 2013; Zu et al., 2013) . Furthermore, nuclear-enriched abundant transcript 1_2 (NEAT1_2), a long non-coding RNA, was demonstrated to bind to TDP-43 and FUS/TLS (products of an ALS-linked gene) in the spinal motor neurons of ALS patients (Nishimoto et al., 2013) . These lines of evidence suggest that abnormal RNA-associated foci generated by dysfunction of ALSassociated genes may act as a scaffold of RNAs and RNA binding proteins in the nuclei of ALS motor neurons, thereby modulating the gene expression that is critical for neuronal survival (Donnelly et al., 2013; Kwak and Kawahara, 2005) . Because ADAR2 downregulation is one death-causing molecular abnormalities demonstrated in ALS motor neurons, scrutiny for the effects of sequestration of gene-regulatory molecules on ADAR2 gene expression may provide us a clue for the mechanism underlying the ADAR2 downregulation and ALS pathogenesis.
Because of the close association of the cascade downstream of ADAR2 downregulation to ALS pathogenesis, enhancement of deficient ADAR2 in the motor neurons to a level sufficient to edit the GluA2 Q/R site may be a logical new therapy for sporadic ALS and the normalization of TDP-43 nuclear localization would be a biomarker for the therapeutic effects in the model animals (Yamashita et al., 2013) .
